ArticleJournal of cellular and molecular medicine2020
The phenotypic changes of γδ T cells in COVID-19 patients.
Article in Journal of cellular and molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Mucosal immune response in biology, disease prevention and treatment.Signal transduction and targeted therapy · 2025Pooled it
- Functional Profile of γδ T Cells in Severe and Moderate COVID-19: A Brazilian Cross-Sectional Study.Cells · 2026Article
- Article
- A systems immunology approach reveals divergent immune profiles of RSV and SARS-CoV-2 infections in infants.Science translational medicine · 2026Article
- Pregnancy and lactation induce distinct immune responses to COVID-19 booster vaccination and SARS-CoV-2 breakthrough infection.JCI insight · 2025Article
- Infants display reduced NK cell responses in RSV and increased inflammatory responses in SARS-CoV-2 infections.Research square · 2025Article
- Expansion of memory Vδ2 T cells following SARS-CoV-2 vaccination revealed by temporal single-cell transcriptomics.NPJ vaccines · 2024Article
- NFκB and NLRP3/NLRC4 inflammasomes regulate differentiation, activation and functional properties of monocytes in response to distinct SARS-CoV-2 proteins.Nature communications · 2024Article
- Adaptive immune cells are necessary for SARS-CoV-2-induced pathology.Science advances · 2024Article
- γδ T-cells in human malignancies: insights from single-cell studies and analytical considerations.Frontiers in immunology · 2024Review
- Immunologic and inflammatory consequences of SARS-CoV-2 infection and its implications in renal disease.Frontiers in immunology · 2024Review
- Post COVID-19 complications and follow up biomarkers.Nanoscale advances · 2023Review
- Review
- Ketogenic Diet and Ketone Bodies as Clinical Support for the Treatment of SARS-CoV-2-Review of the Evidence.Viruses · 2023Review
- Immune responses in mildly versus critically ill COVID-19 patients.Frontiers in immunology · 2023Review
- The dynamics of γδ T cell responses in nonhuman primates during SARS-CoV-2 infection.Communications biology · 2022Article
- Phenotypical and Functional Alteration of γδ T Lymphocytes in COVID-19 Patients: Reversal by Statins.Cells · 2022Article
- Multi-omics personalized network analyses highlight progressive disruption of central metabolism associated with COVID-19 severity.Cell systems · 2022Article
- SARS-CoV-2 Infection: Host Response, Immunity, and Therapeutic Targets.Inflammation · 2022Review
- Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials.International immunopharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
A novel pneumonia-associated respiratory syndrome named coronavirus disease-2019 (COVID-19), which was caused by SARS-CoV-2，broke out in Wuhan, China, in the end of 2019. Unfortunately, there is no specific antiviral agent or vaccine available to treat SARS-CoV-2 infections. The information regarding the immunological characteristics in COVID-19 patients remains limited. Here, we collected the blood samples from 18 healthy donors (HD) and 38 COVID-19 patients to analyze changes on γδ T cell population. In comparison with HD, the γδ T cell percentage decreased, while the activation marker CD25 expression increased in response to SARS-CoV-2 infection. Interestingly, the CD4 expression was upregulated in γδ T cells reflecting the occurrence of a specific effector cell population, which may serve as a biomarker for the assessment of SARS-CoV-2 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.